Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Biotage, Audiocast with teleconference, Q1'24

By Inderes4/25/2024, 1:00 PM
Biotage

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Torben Jørgensen
00:00 - 14:38

And welcome to this webinar on our Q1 results. We will start with just a few slides on who we are, and then we will try to add a little more detail to the executive summary that we have. And then Andrew will guide us through the financial update. Uh, and then hopefully, lots of questions afterwards. So, let's get rolling. I think you have seen this slide before, but it's always good to repeat what kind of company we are? Because, as we have also addressed in our Q1 report, not the least in the CEO's words, we have tried to simplify our strategy going forward and be more clear that we are the global go-to separations company. And as you also know, we do have quite a lot of products that cover workflow solutions for our customers. That includes instrumentation, consumables, and services. And as you can see in the middle of the slide, we are covering more or less all of the stages there are in drug discovery. So we can cater to most types of customers. And of course, to the right of the slides, you see all the modalities that we have in our pipeline and our product portfolio. So, I think we are pretty well equipped for also seeing some interesting growth going forward. Which brings me to the next slide. Just as an executive summary, as you all have seen. Uh, this morning we came out with a top line of 480 million SEK. A 33% growth over last year with a very impressive gross margin of 63.1%, an uptake of 2.2%. And that we are also pretty good at converting our sales to cash, as you can see, we have converted 171 million SEK and having an adjusted EBITDA of 126 million SEK. Uh, as I also wanted to allude to before we get to Andrew's presentation. There has been tremendous growth in our recurring revenue, which is now up at 72%. Some of you know that in the old days, we were fighting to get to this percent, and we have now moved from 67% out of 2023 and now to 72%. And of course, that has to do with the Biotage business that has grown by 78% over the last Q1 in 2023. And as you can also see, our Advanced Therapeutics and Biologics now cover 30% of our business. So, a very good way of going forward with this, with one caveat that we are not happy with, also mentioned in the report. That was that we didn't succeed in getting the core bioscience to a zero level, or as we said last time, a small increase. And you also know the reason, and in a positive way, we say there is tremendous demand in the peptide business. And we were not able to fulfill that demand. Have we had the opportunity to do that? We would have had very good single-digit growth, even in the core business. We're working on it. We are increasing the capacity going forward. And we are still seeing tremendous growth in the peptide area. We are continuing to invest both in manufacturing facilities and in our R&D capabilities around the globe. So with that, I think I have one more slide which I want to just allude to, just to give you a flavor of that. It's not just our current business. We are also launching new products. And you can see the PuraBead Edge. And one of the things we are also constantly having in our mindset is that we need to continue developing products that can be sustainable. And that we are trying to eliminate, let's say, all the solvents we can. And it goes for both sides of the slides and that we are also bringing more products into the PFAS area, going forward. And hopefully, we will see slides also in the next quarter that are also having some instrumentation out in the field as new products. And by that, I hand over the word to Andrew. Thank you, Torben. The business, as just mentioned, had a good start to the year with a solid Q1 performance. We returned to positive organic growth in our key markets in the Americas and EMEA, and we delivered strong recurring revenues at 72% in the quarter. It's worth just pointing out that Biotage is built on sound fundamental foundations of business focused on the traditional small molecule market, delivers predictable revenue streams, industry-leading gross margins, and solid underlying EBITDA and cash generation. Our Biologics and Advanced Therapeutics business, which incorporates Australia, gives us access to the higher growth pharmaceuticals market and the ability to generate superior revenue growth and attractive margins. And as you just heard, our biologics business in Q1 accounted for 30% of our total revenue compared to just 4% in Q1 2023. Coupled with our expansive modality offering and expertise, a further strength of Biotage is its balanced geographical profile, with strong positions in the Americas and EMEA markets, and attractive plays in selective key Asian markets that offer significant medium-term growth opportunities. And as you just heard, in the quarter, we delivered revenues of 480 million, up 33%, gross margins of 63.1%, up 2.2 percentage points, and underlying EBITDA at 126 million, up 28%. We saw very encouraging double-digit growth in EMEA and smaller positive growth in the Americas. But on the flip side, we saw strong gains in China as well. We've seen a marked recent acceleration in customer demand for equipment targeted at the peptide market, which we have been unable to keep fully pace with in the first quarter. We're actively working with our supply partner to ensure additional production capacity is available so that delivery can take place in the required volumes in the coming quarters. Had it not been for this issue, we would have been able to report some quite nice positive organic growth rather than the small negative organic growth of 1.4% reported. Just a few words on Australia: In Q1, Australia delivered 129 million in revenue and a margin of 64.8% compared to Q1 2023. Revenue grew by 78%. Just to reiterate what I've previously commented, Australia is a growing business and not at a stage where it neatly fits into a stable, uniform quarter format like our small molecules business. Of course, we're very pleased with our Q1 growth, but you cannot take that Q1 growth and assume it applies uniformly to the following quarters. It is still lumpy, but what we can say is that we are on course to deliver very pleasing growth year on year, with current market forecasts appropriately reflecting this. In the quarter, we saw growth in biologics and advanced therapeutics, analytical testing, and water and environmental testing. Our small molecule business saw declines driven by suppressed business activity, with APAC heavily impacting this. Our scale-up and diagnostics businesses, which together represent less than 10% of our business, also declined in Q1 with scale-up. The decline was driven by the comparator, with Q1 '23 containing the last remnants of Covid-related business in China. With the diagnostics business. We were again up against some very strong comparators with a very large customer order delivered in Q1 '23. Order intake in both our scale-up and diagnostics businesses is more lumpy. Therefore, you have to focus more on the medium-term trend rather than a particular quarter. At constant exchange rates excluding Australia. Our EMEA business delivered solid organic revenue growth in the quarter of 10%; our Americas business delivered growth of 2%, while our APAC business saw a negative growth of 17% in Q1, driven by China, excluding China. Our revenue in Q1 was consistent with the prior year. Needless to say, we're actively looking at all our businesses on a routine basis to ensure that we are right-sized to ensure continued prosperity. Headwinds in Q1 '24 held back our organic growth by approximately 5 million SEK, or 1%. If we look at our total group business, including Austria, our EMEA and American markets accounted for 83% of our total business, compared to 72% last year, with APAC accounting for the further 17% or 28% last year. Our recurring revenues were very strong, 346 million, representing 72% of our total revenue, compared to 59% last year, with our non-recurring revenues making up the balance of 134 million, or 28%, compared to 41% last year. Higher recurring revenues give us more predictability in our results. Our guiding principle is always to put the customer first and concentrate on forming long-term partnerships with them to solve their problems, improve their workflows and efficiency, and create additional value. In Q1, we delivered an adjusted EBITDA of 126 million, 28% above Q1 last year. In the quarter, we also took approximately 8 million in charges relating to the CEO transition. And as these are one-off in nature, they have been excluded in deriving the adjusted EBITDA total. We delivered a very strong adjusted cash flow from operations of 171 million, 103 million above the prior year, and we finished the quarter with gross cash of 683 million SEK and net cash of 426 million SEK. Also during the quarter, we continued to invest in R&D to be at the forefront of innovation leadership in our markets. We have an attractive R&D pipeline that will power our future growth. As you've just seen from Torben, we continue to launch exciting new products in the quarter, and we're particularly excited about PuraBead Edge. Adapting novel nanofiber technology platform that addresses the challenges of purifying large and fragile modalities, the fast-growing cell and gene therapy markets. So in summary, Biotage has a strong market position with an enviable broad suite of critical must-have solutions in our key markets of drug discovery and development through to diagnostics and analytical testing. We have a clear strategic vision and are resolutely focused on executing on our plans to deliver superior growth at attractive margins. And just a final reminder to everyone that Biotage will be holding a Capital Markets Day on Thursday, 23rd of May in Cambridge. And we would very much like to see as many people as we can, so we can outline how Biotage is evolving and explain in more detail our exciting technology and growth plans. Back to you, Torben. Now, as you have heard, we are facilitating that we can get some guidance. And I want to reiterate what Andrew just said, that we would absolutely encourage as many of you as can come to Cambridge and first of all, have a presentation of other managers in my team and of course, even more, see the site in Cambridge where you will see some of the fantastic new products we are trying to develop. So, by that, we will open for questions.

Unknown
14:43 - 15:06

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Ludwig Lundgren from Nordica. Please go ahead.

Unknown
15:07 - 15:34

Yes. Good afternoon, Torben and Andrew. Thank you for taking my question. So first of all, given the strong growth here, you stated it's 78% year over year growth. And when I tried to back out some type of seasonality for last year, I get that it was a sequential increase throughout the year. Maybe this is more related to the scale-up of the business than the seasonality, but can we expect some type of similar seasonality for this year?

Torben Jørgensen
15:36 - 16:45

Well, I think what we obviously we're not giving guidance on, um, the quarter by quarter performance of Australia. It's um, you know, we're happy with the Q1 performance. And yes, it was a lot better than Q1 23. Um, you know, we're very happy we've got a growing business. And, you know, will that growth be a nice linear upward line? Probably not. I mean, life I suppose is never like that. Anyway. Um, there will be lumpiness in the revenues in the quarter. Uh, but you know, we have got a nicely strong growing business. And of course, as our business grows and develops and matures, you know, we'll start to see a more normal phasing pattern. But we're still in that process or in that stage of understanding what is that normalized phasing of the business. Therefore, you know, I wouldn't necessarily read too much into a quarter by quarter performance. Keep your eye on the bigger picture, on the yearly growth, um, of Australia.

Unknown
16:47 - 17:09

Okay. Thank you. That's very helpful. Um, and then, uh, also on, um, maybe focus on the small molecules business. Uh, here it was a continued decline year over year. Uh, but maybe if you could dig in a bit into the dynamics throughout the quarter, like, uh, how was, for example, the exit rate out of Q1 was it stronger than the start and so forth.

Torben Jørgensen
17:11 - 19:13

You can say that, first of all, I think it's um. It's not bad to get as close as 1.4% negative gross margin. We would have liked to be on top of it. There are differentiations in where it is that the gross margin, because if you look at some of the areas around it, then there are areas where it's still growth. We could see also that the peptide business is booming. And it's not just from one area, it's all three regions where there are booming incoming orders and requests. The analytical business is also coming back after the Covid times. So we see a really nice uptake. It is, as Andrew said, we are really facing not only headwind but a storm in China. And I would also say we are not, as I may have said before, trying to see some light at the end of the tunnel for China in the coming quarters. I don't think we will see that either. It is extremely tough there. I would say Japan and Korea are in reasonably good shape and we have seen some encouraging orders coming in recently. So, it's still tough out there and people are keeping tight on their money, but we are seeing progression. We are also hoping to see that the downturn we have seen in China is going to be less over the coming quarters, but it will still be very, very tough times over there.

Unknown
19:16 - 19:35

Right, I got it. So then maybe you mentioned the peptides. So with this increase in demand and you were not even able to deliver on all of the demand, if I understand correctly, do you think this will release a new trend that will be sustained throughout the year, or is this just a temporary thing?

Torben Jørgensen
19:35 - 20:55

No, I don't think that it is just a one-year situation. We strongly believe that the demand will stay pretty good for the coming years. So our focus is to ensure that we get much more manufacturing capabilities. And to that end, I can say I visited our supplier a couple of weeks ago just to make him very well aware of what our demands are. And, the positive thing I saw was that there were new machines there that are up and running already, and we can expect to see progress in being able to deliver more in Q2 and forward. We still have work to do to get up to the level where we want to be. Because it is more than double of what the capacity was a quarter ago. So I would say, no, we don't see it as a one-year lump up. It's hopefully going to continue. And that's what we are seeing.

Unknown
20:58 - 21:04

Okay. Thank you. That's all. That's all for me. Thanks very much for taking my questions. Thank you.

Unknown
21:10 - 21:16

The next question comes from Simon Larsen from Danske Bank. Please go ahead.

Unknown
21:17 - 21:43

A few questions, please, from my side as well. Continuing a bit on the peptide purification business, how much do you estimate that you lost or maybe, let's say, pushed out in the peptide business here in Q1? You mentioned very good single-digit growth. Haven't you sort of missed out on the deliveries? Are we talking more than 20 million SEK here that you pushed out, so to speak, or what? Yes.

Torben Jørgensen
21:43 - 21:47

Actually, we want to give you a number of 35 million SEK.

Unknown
21:48 - 21:48

Yes. Okay.

Torben Jørgensen
21:49 - 21:54

Well, if you translate that, we would have been reporting an 8% organic growth.

Unknown
21:55 - 22:08

You know, that's very impressive. Okay. Thank you a lot for that. And, I mean, I didn't quite catch what Torben said here in response to the final question before me. But do you expect to start delivering on that already here in Q2? Will that take some time?

Torben Jørgensen
22:09 - 22:57

It will take more than Q2 to get to that level because, as you can understand, with 36 million. And let me also say, new orders are already coming in for Q2, so we will not be able to clean everything in Q2, but we will deliver more than we have done in Q1. And on a good day, I hope that we will get closer there in Q3. But there is work that needs to be done, more than just having two new machines. So, they need to increase their manufacturing capabilities going forward. And that's why we are in ongoing dialogue with them as we speak.

Unknown
22:58 - 22:59

Understood. Yes.

Unknown
23:00 - 23:15

That makes sense. Makes sense. I mean, the weakness in instrument sales. Could you give any more insight into that? I mean, is it primarily due to a weak Chinese CRO CDMO market for small molecules like flash chromatography systems, or is it something else that's dragging here?

Torben Jørgensen
23:17 - 24:07

I would say that it is predominantly the flash purification. And of course, China is the major, let's say the place where it has gone down. As you can see what Andrew said, we have growth in MDL of 10%. So, the business is going quite well. We are also experiencing growth in the US. Not as significant as in the MDL, but there is growth. It is. And I must say, it is extremely tough out of China. Of course, the comparison numbers going forward are going to be better, but we are more focused on the nominal business. Uh, and that is tough.

Unknown
24:09 - 24:24

Yes. And the final question from my side. So I noticed roughly 30 people fewer employed in Q1 versus Q4. So you obviously let go of a few people here during the quarter. Should we expect this to show in the P&L going forward in any way? Uh.

Torben Jørgensen
24:26 - 24:43

Um, no, I don't know. Don't be sad. You know, it's just a general trend of joiners and leavers, you know. So, yeah, we've not been, you know, businesses, uh, not in any kind of, uh, so it's just a normal trending pattern. So I wouldn't, uh, read too much into that, too much into quarter-to-quarter numbers. So I'm.

Unknown
24:45 - 24:47

Okay. Yeah, okay. Makes sense. Thanks a lot, guys.

Unknown
24:52 - 24:57

The next question comes from Carl Nolan from SEB. Please go ahead.

Unknown
25:02 - 25:20

Yes. Hello. Uh, uh, some questions for myself as well. If we start on the analytical testing side, which I think was very strong this quarter, quite a bit from recent quarters, to just mention anything specifically that drove this growth and any new customer signs or a new contract going on.

Torben Jørgensen
25:22 - 26:02

I would say that it is getting the business back. We had before Covid. It's all, let's say CEOs in or the big LabCorp and Quest. They are getting back to the normality of having tests of many, many other samples than just for Covid. Uh, I wouldn't say that there is any one big ticket that has come into play, uh, that we haven't had before. So it is just normalizing the business. Uh, getting back to where we were before Covid.

Unknown
26:04 - 26:07

Okay. Sounds good. And one thing about.

Torben Jørgensen
26:07 - 26:23

The verdict on that is that analytical testing is great; it's a great sticky business and a great source of high recurring revenue. So, you know, you're playing consumables into said Quest and LabCorp and all the, you know, so it's a great source of high recurring revenue for us.

Unknown
26:24 - 26:46

Yeah, exactly. That was why I was a bit surprised by the uptake here in the first quarter. But it sounds good if it's sticky. Another question here. Uh, moving on to the bio, which is down 3% year over year. Could you comment on what's going on in that business?

Torben Jørgensen
26:47 - 27:30

Yes, I think it's fair to say that it's lumpy. It's a lumpy business. It depends on the order intake. You know, we're comparing against a very high quarter, Q1 2023. So I think what we've got to do with the diagnostics as well as the startup businesses is really kind of look at more of a trend rather than a particular quarter because a particular quarter is dependent on kind of order intake and being able to recognize revenue. So let's give those businesses a few quarters to see the real trends, rather than necessarily get worried or not by just one particular quarter. Uh, okay.

Unknown
27:30 - 27:50

And then just a question on slide 3 as well. I don't know if you answered before, but I'm just backed out here. The Q1 numbers last year from Biotage, it seems to be around 84 million. Uh, and on the seasonality side, in Australia, are Q1 and Q2 usually similar sales levels, or do they differ a lot?

Torben Jørgensen
27:51 - 28:54

Um, it's again, we, we, we, um, you know, we've got to see more trends to, to, to give you that maybe kind of if we hear next, next year, this time we can probably start giving you more reliable because we'll have more reliable commentary. So we'll have more of a history of what the normalized trends and phasing of Australia are. Obviously, it's a growing business. It's attracting new customers. We just need to see how that's developing and how the customers are giving orders generally. I mean, I think others have commented, Danaher and so on, about the kind of gradual return of customers coming back. So, you know, we still think, as we said previously, that it's going to be more weighted to H2 than H1. And we feel comfortable with our kind of total yearly target. But you know.

Unknown
28:54 - 29:01

It's going to be, I mean, were you surprised by the 7 to 8% growth in Australia here in Q1?

Torben Jørgensen
29:02 - 29:10

Um. It's nice. I'm not going to say I'm not going to. I'm going to be giving a running commentary about the kind of weather. We're pleased. Yeah, we were, we were, you know, we were happy with it.

Unknown
29:12 - 29:36

Yes, and if I may just add one on small molecules as well. I mean, sales are down to the lowest level in quite a while. And I understand it, China is much behind this. But I also noticed America was down a little bit. So, I was wondering, do you feel like a run rate around 140 million in sales per quarter? That's roughly where it should be. Or is there potential to increase that going forward?

Torben Jørgensen
29:37 - 30:24

I would say the following. We would absolutely like to see the trend growing. We know that there is a lot of work to get that going. There are also pockets of areas where we absolutely can grow going forward. And we are, of course, also working on getting some more products out. So we are still developing products in the area of small molecules and our instrumentation platform. Hopefully, within the not too distant future, you will see some news coming out in that area. So would we like to see a better baseline? Absolutely. And we are working on it.

Unknown
30:27 - 30:32

Good. Sounds promising. See you in Cambridge, then. Torben and Andrew.

Torben Jørgensen
30:33 - 30:34

Yeah. Looking forward to it.

Unknown
30:41 - 30:47

The next question comes from Matthias Blom from Handelsbanken. Please go ahead.

Unknown
30:48 - 30:48

Yeah.

Torben Jørgensen
30:48 - 30:49

Good afternoon. My

Unknown
30:51 - 31:18

Two questions, please. Firstly, while you've said a lot about what Australia did in the quarter compared with last year, why you can't say how you feel about Q2 yet, but maybe a year from now we'll know more about seasonality. Is there anything you can say in terms of customer concentration or the opposite, diversification for Australia in the quarter? And I think that changed during this quarter compared to, for instance, Q4.

Torben Jørgensen
31:19 - 32:38

No, I don't think there's anything materially different about the Australian business in Q1. Obviously, our whole commercial strategy is to expand that customer base and drive further diversification. But you know that that is more of a medium-term thing rather than just an immediate quarter issue. So, you know, it is a similar business to what we saw last year. But I would like to say also, as Andrew alluded to, we are increasing the customer base quarter by quarter and by. This gives us better opportunities going forward to have a better view. It's not that we never give you any prognosis, but we are still on a learning curve also to see how the seasonality is. But of course, it's getting better and better the more customers we get and the more significant orders we can get from these customers. But we are really looking at this business on a yearly basis to see if we are satisfied with the growth that we are expecting.

Unknown
32:40 - 32:48

That's clear. Anything you can say about the book-to-bill for Australia? Or is that not useful? You know.

Torben Jørgensen
32:49 - 33:07

I think it's probably too early, the business is too early in its growth trajectory to use book-to-bill as a good ratio for stable, established businesses. I think it would just be, you know, a fairly meaningless number right now.

Unknown
33:08 - 33:29

Gotcha. And then finally, ahead of the Capital Markets Day coming up in May, what in particular is the ambition to get across to the investor community? Joining on-site, I mean, what in your view remains a gap in terms of perception to better understand Biotage? Any commentary that would help me frame the expectations would be appreciated.

Torben Jørgensen
33:33 - 35:21

Um, well, I can go first, I think. Yeah, what we wanted, you know, obviously to have it in Cambridge is for people to get more of an understanding of Australia, you know, kind of actually see it, physically hold products. Um, hear from, you know, our great leadership in Australia about, you know, the kind of exceptional growth journey they're on and what products and technology they have, but also kind of a wider Biotage. You know how our business is evolving, how we're positioning our business to win in the markets. So you know it's kind of a holistic view. But obviously, in Cambridge with slightly more of an emphasis on our biologics business. And I would add to that, it's also to get exposure to other parts of my management team so that you don't have to listen to Andrew and me all the time. Get also some of the people that are doing the job in the machine room every single day that they have a chance to meet with you guys, and so they will be more exposed than anyone else in that setting. And of course, as Andrew said, to look at what we believe is a very, very bright future from a technology that is not even out there yet. Really, it's just in the testing phase. And therefore, we took the decision to go to the UK.

Unknown
35:23 - 35:25

Perfect. That's all for me. Thanks so much.

Unknown
35:33 - 35:39

The next question comes from Odysseus Minnesotas from Berenberg. Please go ahead.

Unknown
35:41 - 35:42

Hi.

Andrew Kellett
35:42 - 36:13

Thanks for taking my questions. One for Andrew first. So, Andrew, you said that current market forecasts were in line with your expectations for Australia. I just wanted to make sure what you're referring to. Is this the sort of consensus which has Austria or your biomolecules business at 650 to 700 million sector a year? Or is it more like your targets, which imply an annual growth of 30% sales annually here?

Torben Jørgensen
36:13 - 37:07

Yes. We don't just provide guidance. Obviously, we do look at the reports that come out and, you know, for me, it's whether I kind of fall off my chair or not. I'm not. So, you know, we think the current values that people have penciled in probably chime with our views of the business. Obviously, what I do want to do is get people to say, you know, Austria had a 78% growth in Q1. Wow, that. So if I start doing the numbers, we get to a crazy number. So it's providing some bookends so people can know yes, we've got a good growing business. But let's not get too carried away at this early stage. So that's kind of what I wanted to get across there.

Andrew Kellett
37:08 - 37:25

Understood. And could you share a bit more detail on China just to help us model here? So what was the, as a percentage of your sales or an absolute number in Q1? And what was it in full year 23?

Torben Jørgensen
37:26 - 38:50

I think what we can say in a more broad setting is at a certain stage, China was covering 15% of Biotage's business. Now we are below 5%. And with all of the political games that are going on in the world right now, would I like to see China a little bit better? Yes. Do I want to see them at 15%? No way do I want that, because that's too scary. So, there are good and bad things about it because we're still growing the business and China plays a smaller and smaller role. And, it's a strong situation to be in with respect to. We need to, of course, look at how our structure in China is going forward. Because if this continues, that, for instance, the US is abandoning any business more or less with some of the big CROs there, then, as you know, they have been our primary customers over the last couple of years. So, but just to give you a bit of a framework. We've gone from 15% down to below 5%. Today.

Andrew Kellett
38:52 - 39:29

Understood. Very clear. Thanks, Torben. And thirdly, could you be a bit more specific on the peptide benefit here? I understand you launched the extra Hera. Your new extra Hera. And you also announced a big partnership at the end of last year. That probably helped. Was it? What I'm trying to understand is this. And mainly product launch-dependent growth, or was there anything market-wide that benefited you? Here? Is it the GLP-1 situation? Uh, is it relevant to you?

Torben Jørgensen
39:30 - 40:23

That said, let me say the following. First of all, we have what we think is a pretty unique situation helping our customers with their workflow of synthesizing, purifying, and evaporating their products. And in the front end of the synthesis, the Syro instruments are a parallel synthesis that can make 96 peptides at a time. That's very helpful for customers building libraries. So, that's what it is. We haven't right now added some very specific new products to the pipeline. It's just that we have a good solution for the customers that need to manufacture quite a lot of peptides.

Andrew Kellett
40:26 - 40:42

Understood. And the last one for me. Uh, on the water front. I understand you don't share details here, but could you at least tell us from a sequential perspective? Uh, did either orders on an absolute basis grow from Q4 to Q1?

Torben Jørgensen
40:44 - 42:20

I think in the coal business, um, it's pretty similar, you know, small molecules. Uh, we, you know, the order intake is pretty consistent. You know, if you look at our small molecule business, it's a nice, relatively stable business, even with, you know, that, you know, kind of one of the strengths, one of the, you know, we suffered a big fall in China but had growth in EMEA and America. So they're kind of counteracting each other, which is kind of a nice position to be in. And it's also one thing that you have to remember when. How is the outlook for, let's say, the internal people to make prognosis and forecast? When you are in this small molecule area, you sometimes don't have 45 days. The outlook because they don't get them to commit to anything. And right now, it's always in the last minute. Okay. Now we got the order. I would say we have seen some positive trends in some areas. And of course, we're still seeing, as we have now alluded to quite a few times in this call, that China is not starting to take off in any major ways, but there are pockets in other areas that are seeing some interesting growth. And also, orders and the backlog and quotes.

Andrew Kellett
42:24 - 42:27

Thank you very much. That's perfect to hear. So, you're in Cambridge?

Torben Jørgensen
42:28 - 42:28

Just.

Unknown
42:34 - 42:57

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Torben Jørgensen
42:58 - 43:23

First of all, thanks for participating, listening, and also your questions. And let me reiterate, I hope to see as many of you in Cambridge in a month's time. Uh, it'll be fun. And, uh, we really have something to show you. So, um, uh, get over there. And thanks for today.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…